CAR-T Cell Therapy market Analysis and Trends by 2022-2035

[jameshebrew]

As the six approved CAR-T cell therapies, including Breyanzi®, Abecma™ and CARVYKTI™ are poised to achieve blockbuster status, along with a promising development pipeline, the field of CAR-T cell therapies has gained significant traction

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035.”

The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:
 A detailed assessment of the current market landscape of CAR-T-cell therapies.
 An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors.
 A detailed analysis of completed, ongoing and planned clinical studies related to CAR-T cell therapies.
 An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T cell therapies.
 Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above).
 An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T-cell therapies.
 An analysis of the investments that have been made into companies that have proprietary CAR-T cell-based products / technologies.
 An in-depth analysis of patents related to CAR-T cell therapies, filed / granted till 2022.
 A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
 An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
 A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies.
 Elaborate profiles of the several leading players in the domain of CAR-T cell therapies.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
 Target Indication(s)
 Non-Hodgkin’s Lymphoma
 Multiple Myeloma
 Acute Lymphoblastic Leukemia
 Chronic Lymphocytic Leukemia
 Hodgkin’s Lymphoma
 Acute Myeloid Leukemia
 Ovarian Cancer
 Generalized Myasthenia Gravis (MG)
 Renal Cell Carcinoma

 Target Antigen
 CD19
 BCMA
 CD19/22
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

Transcripts of interviews held with the following senior level representatives of stakeholder companies:
 Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
 Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
 Miguel Forte (Chief Operating Officer, TxCell)
 Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
 Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
 Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
 Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
 Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
 Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about CAR-T-cell based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to CAR-T cell immunotherapies and manufacturing capabilities of the players.

 Autolus
 bluebird Bio
 Bristol Myers Squibb
 Carsgen Therapeutics
 Cellectis
 Cellular Biomedicine Group
 Gilead Sciences
 Innovative Cellular Therapeutics
 Kuur Therapeutics
 Noile-Immune Biotech
 Novartis
 Shanghai GeneChem
 Sinobioway Cell Therapy
 Takara Bio
 Wellington Zhaotai Therapies

Get more details on the CAR-T Cell Therapy Market report https://www.rootsanalysis.com/reports/view_document/car-t-therapies...

You may also be interested in the following titles:
DNA Encoded Libraries
Quantum Computing in Drug Discovery Services Market

You may also like to learn what our experts are sharing in Roots educational series:
mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule

TIL Therapies: A New Paradigm in Cancer Treatment


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
[phone]
[e-mail]